Log in

NASDAQ:ZFGNZafgen Stock Price, Forecast & News

$1.09
+0.22 (+25.29 %)
(As of 05/25/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.88
Now: $1.09
$1.09
50-Day Range
$0.73
MA: $0.83
$1.09
52-Week Range
$0.62
Now: $1.09
$2.83
Volume3.21 million shs
Average Volume247,867 shs
Market Capitalization$40.84 million
P/E RatioN/A
Dividend YieldN/A
Beta0.27
Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.
Read More
Zafgen logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.45 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ZFGN
CUSIPN/A
Phone617-622-4003

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.43 per share

Profitability

Net Income$-45,410,000.00

Miscellaneous

Employees38
Market Cap$40.84 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive ZFGN News and Ratings via Email

Sign-up to receive the latest news and ratings for ZFGN and its competitors with MarketBeat's FREE daily newsletter.

Zafgen (NASDAQ:ZFGN) Frequently Asked Questions

How has Zafgen's stock been impacted by COVID-19 (Coronavirus)?

Zafgen's stock was trading at $0.8501 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ZFGN stock has increased by 28.2% and is now trading at $1.09. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Zafgen?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zafgen in the last year. There are currently 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Zafgen.

When is Zafgen's next earnings date?

Zafgen is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Zafgen.

How were Zafgen's earnings last quarter?

Zafgen Inc (NASDAQ:ZFGN) announced its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter. View Zafgen's earnings history.

What price target have analysts set for ZFGN?

5 analysts have issued 1 year price targets for Zafgen's shares. Their forecasts range from $0.78 to $5.00. On average, they expect Zafgen's stock price to reach $2.89 in the next twelve months. This suggests a possible upside of 165.1% from the stock's current price. View analysts' price targets for Zafgen.

Has Zafgen been receiving favorable news coverage?

News coverage about ZFGN stock has trended negative this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Zafgen earned a coverage optimism score of -2.7 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutZafgen.

Are investors shorting Zafgen?

Zafgen saw a decline in short interest in May. As of May 15th, there was short interest totaling 523,100 shares, a decline of 9.4% from the April 30th total of 577,100 shares. Based on an average trading volume of 182,000 shares, the short-interest ratio is presently 2.9 days. Currently, 1.8% of the shares of the company are sold short. View Zafgen's Current Options Chain.

Who are some of Zafgen's key competitors?

What other stocks do shareholders of Zafgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zafgen investors own include CA (CA), SCYNEXIS (SCYX), Endologix (ELGX), Energy Transfer LP Unit (ET), TG Therapeutics (TGTX), BlackRock (BLK), Fate Therapeutics (FATE), Pfizer (PFE), Esperion Therapeutics (ESPR) and Gilead Sciences (GILD).

Who are Zafgen's key executives?

Zafgen's management team includes the following people:
  • Mr. Jeffrey S. Hatfield, CEO & Director (Age 61)
  • Ms. Patricia L. Allen, Chief Financial Officer (Age 57)
  • Dr. Dennis D. Kim M.D., MBA, Chief Medical Officer (Age 49)
  • Dr. James E. Vath, Head of Discovery & Devel. (Age 58)
  • Mr. Brian P. McVeigh, Chief Bus. Officer (Age 46)

What is Zafgen's stock symbol?

Zafgen trades on the NASDAQ under the ticker symbol "ZFGN."

Who are Zafgen's major shareholders?

Zafgen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Sphera Funds Management LTD. (8.44%), Soleus Capital Management L.P. (3.60%), Orbimed Advisors LLC (2.95%), Russell Investments Group Ltd. (0.70%), Two Sigma Investments LP (0.60%) and Two Sigma Advisers LP (0.57%). View institutional ownership trends for Zafgen.

Which major investors are selling Zafgen stock?

ZFGN stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Russell Investments Group Ltd., Hikari Power Ltd, and Two Sigma Advisers LP. View insider buying and selling activity for Zafgen.

Which major investors are buying Zafgen stock?

ZFGN stock was purchased by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Soleus Capital Management L.P., and Orbimed Advisors LLC. View insider buying and selling activity for Zafgen.

How do I buy shares of Zafgen?

Shares of ZFGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zafgen's stock price today?

One share of ZFGN stock can currently be purchased for approximately $1.09.

How big of a company is Zafgen?

Zafgen has a market capitalization of $40.84 million. The biopharmaceutical company earns $-45,410,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Zafgen employs 38 workers across the globe.

What is Zafgen's official website?

The official website for Zafgen is www.zafgen.com.

How can I contact Zafgen?

Zafgen's mailing address is 3 Center Plaza Suite 610, BOSTON MA, 02108. The biopharmaceutical company can be reached via phone at 617-622-4003 or via email at [email protected]

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.